Syremis Therapeutics

Launched in December 2025 with $165M Series A to develop best-in-class medicines for severe mental illness. Two programs spun out of Clexio Biosciences: ST-905, a dual M1/M4 muscarinic agonist in Phase 1 for schizophrenia, and ST-901, an NMDA antagonist in IND-enabling studies for major depressive disorder and bipolar depression. Co-founded by CEO Elisabeth Kogan and Steve Paul MD (former Karuna Therapeutics CEO/Chair). Dual headquarters in Tel Aviv and Boston.